Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and predictability in the base businesses of two key biotech leaders.
The top analyst upgrades, downgrades and initiations seen on Thursday included AK Steel, Amgen, Booking, Chubb, Chipotle Mexican Grill, Expedia, Gilead Sciences, Goodyear, Philip Morris, Target and Zscaler.
24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new ideas for investors and traders alike. Some of these analyst reports cover stocks to buy,…
The April 30 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The April 15 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how…
Jefferies did a deep dive into the health care sector, looking for underperforming stocks that could hold some solid value going forward.
The March 29 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The February 28 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The February 15 short interest data have been compared with the previous report, and short interest in most…
Here are five top health care stocks that recently saw their 50-day moving average cross below the 200-day average, a death cross.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The January 31 short interest data have been compared with the previous report, and short interest in most…
There is great opportunity in healthcare. There is also quite a lot of risk. Politicians and consumers alike want lower drug prices. Patients want the best of the best options for devices,…
The January 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
